Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.

Cancer discovery - 1 Nov 2014

Abstract excerpt

The combination of erlotinib and bevacizumab prolongs PFS in patients with EGFR-mutant NSCLC.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 25367959
DOI: 10.1158/2159-8290.CD-RW2014-194

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.PMID 25367959Read ↗

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.Semantic proximity Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.Semantic proximity Read ↗

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.Semantic proximity Read ↗

Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.Semantic proximity Read ↗

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.Semantic proximity Read ↗

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.Semantic proximity Read ↗

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.